A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

NCT01353664 PHASE2 COMPLETED Results posted

This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.

Details

Lead sponsor	Celgene
Phase	PHASE2
Status	COMPLETED
Enrolment	19
Start date	Sun May 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lymphoma
• Cancer

Interventions

• Romidepsin

Countries

United Kingdom, United States